Choose a channel
Check out the different Progress in Mind content channels.
Progress in Mind
Welcome to Progress in Mind’s live coverage of ECNP 2021. This 34th Congress of the European College of Neuropsychopharmacology – Lisbon 2021 started today, October 2nd, using the latest technology to provide an exciting live and connected virtual experience, Hybrid, for all those presenting and attending worldwide. We will be bringing you highlights in schizophrenia, depression, Alzheimer’s disease and general considerations in psychiatry over the next few days. Here is a summary of today’s (Day 1) highlights, and we hope you enjoy Day 2 tomorrow, as engaging, inspirational and thought-provoking as today.
A focus on best practice
Six Satellite Symposia took place
Early assessment and treatment, and functional recovery are key focal points
Impacts of the COVID-19 pandemic
Undoubtedly, the COVID-19 pandemic has changed healthcare and clinical trial practices and two ‘Innovative Format’ sessions focused on this.
Digital medicine has been transformed very much during the COVID-19 pandemic
Expanding our understanding of psychiatric conditions
Four symposia explored some key factors in neurobiology:
Key topics include addressing hyper-aggression; understanding how neurological sex differences can affect treatment; the importance of the gut-brain axis; and identifying immune-inflammatory abnormalities
The Keynote Session, by Professor Ray Dolan, discussed how the hippocampus and related structures, as well as the ventro-medial prefrontal cortex, are involved in building and updating our mental models of the world and the importance of neural replay in the expression of psychopathology.
For more details and information, please visit ECNP official website and follow us in PIM-RC with more summary articles.
Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.
1. Silva MA, Restrepo D. Rev Colomb Psiquiatr (Engl Ed) 2019, 48, 252−260.
2. Larson, M. K.; Walker, E. F.; Compton, M. T. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother 2010, 10, 1347−1359.
3. Correll CU, et al. JAMA Psychiatry 2018, 75, 555−565.
4. Solmi M, et al. World Psychiatry 2020, 19, 214−232.
5. Kaar SJ, et al. Neuropharmacology 2020, 172, 107704.
6. Fiorenzato E, et al. PLoS One 2021, 16, e0246204.
7. Read J, et al. Psychiatry Res 2014, 216, 67−73.
8. Christensen MC, et al. J Affect Disord 2020, 263, 258−266.
9. Cupaioli FA, et al. Prog Neuropsychopharmacol Biol Psychiatry 2021; 106: 110059.
10. Wierenga LM, et al. Hum Brain Mapp 2020; Oct 12: doi: 10.1002/hbm.25204
11. Peris-Sampedro F, et al. Nutrients 2021; 13: 3101.
12. Benros ME, et al. JAMA Psychiatry 2013; 70: 812−820.